Safe heritable embryo genome editing
Editing a one-cell human embryo so that every cell of the resulting person carries the intended change and nothing else.
State of the art
Preclinical embryo and embryonic-stem-cell editing programs announced by Preventive (2025) and Origin Genomics (2026); mitochondrial donation by pronuclear transfer produced eight healthy babies in the UK (NEJM, 2025), the only sanctioned heritable-change clinical pathway.
- Mosaicism - edits arrive after the first division, so cells of the same embryo differ
- On-target large deletions, chromosome loss and chromothripsis occur in edited embryos and are invisible to biopsy-based testing
- A biopsy of a few cells cannot certify the genome of the whole future person, so safety cannot be established before a birth
Who’s working on it
- Preventive ↗Startup
Public-benefit corporation announced October 2025 with about $30M - the largest known investment in heritable genome editing - to run preclinical safety research and publish even a negative answer
- Lucas HarringtonResearcherPreventive
Founder; did his PhD in Jennifer Doudna's lab and co-founded Mammoth Biosciences, and has committed publicly not to advance to clinical use if safety cannot be established
- Shoukhrat MitalipovResearcherCenter for Embryonic Cell and Gene Therapy, Oregon Health & Science University
Ran the first US human embryo-editing experiments (2017) and the nuclear-transfer oocyte work reported in 2025; consults for embryo-editing startups
- Paula AmatoResearcherOregon Health & Science University
Reproductive endocrinologist on the US embryo-editing team and the one established scientist who agreed to advise Preventive (2025)
- Dieter EgliResearcherColumbia University
Studies what actually happens when a human embryo's DNA is cut, including the chromosome-loss and large-deletion failure modes that are the central safety obstacle
- Fyodor UrnovResearcherInnovative Genomics Institute, University of California, Berkeley
Leading gene-editing scientist and the field's most prominent critic of heritable editing, arguing in 2025 that these ventures should not proceed at all
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Whole-genome single-cell validation methods on edited embryo models to quantify mosaicism and structural damage rates | $$ $10M – $100M |
| policy | International oversight and registry framework defining what preclinical evidence would ever justify a first clinical use | $ < $10M |
Depends on
Required by
No other capability builds on this directly.